---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030493"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:02:38.250823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene Q3 net loss narrows to $2.4M; ALS drug shows survival benefit, receives $45.1M NIH grant

## Summary
- Net loss $2.4M ($0.02/sh) vs $11.0M ($0.17/sh) in Q3 2022; R&D expense $6.0M.
- Cash $42.1M as of Sep 30, 2023, expected to fund operations into Q3 2024.
- CNM-Au8 in ALS: 19.3-month median survival benefit in RESCUE-ALS OLE; 49% decreased death risk in HEALEY vs PRO-ACT historical controls.
- Awarded $45.1M NINDS/NIH grant for expanded access of CNM-Au8 in ALS.
- FDA regulatory discussion planned for Q4 2023 to accelerate ALS submission path.

## SEC filing metadata
- accession: 0001437749-23-030493
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/0001437749-23-030493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/clnn20230829_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030493
- JSON: https://secwatch.observer/filing/0001437749-23-030493.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030493.txt

## Key facts
- Earnings Releases
  Clene Inc. reported third quarter 2023 results: net income $2.4 million, EPS $0.02 per share.
  - Period: third quarter 2023
  - Net income: $2.4 million
  - EPS: $0.02 per share
  - Result: reported results
  source text: Clene reported a net loss of $2.4 million, or $0.02 per share, for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/0001437749-23-030493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.